Clinical Laboratory Report

MedPlus Diagnostics

Department of Microbiology

Name	**MRS B MANJULA**	**Order**	**PTGOC2200091991**
Age / Sex	**35 / F**	**Sample Drawn At**	**2022-09-26 12:30:17**
Collection Centre	**INTGHYD95214**	**Sample Accepted At**	**2022-09-26 16:46:05**
Referral Doctor	**SELF**	**Sample Reported At**	**2022-09-26 19:20:01**
		Report Status	**Final**

Mantoux TB Skin Test

SampleType: LOCAL PROCEDURE

INVESTIGATION	RESULT	UNITS	BIOLOGICAL REFERENCE INTERVAL
Mantoux	0 mm		

Given date:24/09/2022 12:25pm Measuring date:26/09/2022 12:25pm Erythema : Absent

Note: * If the test results are alarming or unexpected, client is advised to contact the laboratory immediately for possible remedial action.

Department of Serology

Name	**MRS B MANJULA**	**Order**	**PTGOC2200091991**
Age / Sex	**35 / F**	**Sample Drawn At**	**2022-09-24 12:21:06**
Collection Centre	**INTGHYD95214**	**Sample Accepted At**	**2022-09-24 17:51:09**
Referral Doctor	**SELF**	**Sample Reported At**	**2022-09-24 21:35:54**
		Report Status	**Final**

HIV 1 & 2 Antibody (ELISA)

SampleType: Serum

INVESTIGATION	RESULT	UNITS	BIOLOGICAL REFERENCE INTERVAL
HIV 1 & 2 Antibody Method: ELISA	0.43	Index Value	< 1.00:Non-Reactive > 1.00:Reactive

Note: * If the test results are alarming or unexpected, client is advised to contact the laboratory immediately for possible remedial action.

Department of Serology

Name	**MRS B MANJULA**	**Order**	**PTGOC2200091991**
Age / Sex	**35 / F**	**Sample Drawn At**	**2022-09-24 12:21:06**
Collection Centre	**INTGHYD95214**	**Sample Accepted At**	**2022-09-24 17:50:08**
Referral Doctor	**SELF**	**Sample Reported At**	**2022-09-24 21:35:25**
		Report Status	**Final**

Rapid Plasma Reagin Test

SampleType: Serum

INVESTIGATION	RESULT	UNITS	BIOLOGICAL REFERENCE INTERVAL
Rapid Plasma Reagin (RPR)- VDRL Method: LATEX AGGLUTINATION	Non Reactive		

Note: * If the test results are alarming or unexpected, client is advised to contact the laboratory immediately for possible remedial action.

Department of Serology

Name	**MRS B MANJULA**	**Order**	**PTGOC2200091991**
Age / Sex	**35 / F**	**Sample Drawn At**	**2022-09-24 12:21:06**
Collection Centre	**INTGHYD95214**	**Sample Accepted At**	**2022-09-24 17:51:09**
Referral Doctor	**SELF**	**Sample Reported At**	**2022-09-26 11:29:05**
		Report Status	**Final**

Hepatitis B Profile

Hepatitis B Core Antibody, IgM

SampleType: Serum

INVESTIGATION	RESULT	UNITS	BIOLOGICAL REFERENCE INTERVAL
Hepatitis B Core Antibody IgM (Anti HBc-IgM) Method: CHEMILUMINESCENCE	2.5	PANBIO UNITS	< 5 : Negative 5-10: Equal > 10: Positive

Method: CLIA

This assay aids in the diagnosis of acute or recent (usually six months or less) hepatitis B viral infection.

IgM anti-HBc arises early in the illness of patients with acute hepatitis B, but it rapidly decreases in titre. HBV core IgM levels are generally not detectable 6-24 months after the onset of illness

Note: * If the test results are alarming or unexpected, client is advised to contact the laboratory immediately for possible remedial action.

Department of Serology

Name	**MRS B MANJULA**	**Order**	**PTGOC2200091991**
Age / Sex	**35 / F**	**Sample Drawn At**	**2022-09-24 12:21:06**
Collection Centre	**INTGHYD95214**	**Sample Accepted At**	**2022-09-24 17:50:08**
Referral Doctor	**SELF**	**Sample Reported At**	**2022-09-24 21:35:21**
		Report Status	**Final**

Hepatitis B Profile

Hepatitis B Surface Antigen - HBsAg Rapid Test

SampleType: Serum

INVESTIGATION	RESULT	UNITS	BIOLOGICAL REFERENCE INTERVAL
Hepatitis B Surface Antigen Method: HEPACARD	NEGATIVE		

Note: * If the test results are alarming or unexpected, client is advised to contact the laboratory immediately for possible remedial action.

Department of Serology

Name	**MRS B MANJULA**	**Order**	**PTGOC2200091991**
Age / Sex	**35 / F**	**Sample Drawn At**	**2022-09-24 12:21:06**
Collection Centre	**INTGHYD95214**	**Sample Accepted At**	**2022-09-24 17:51:09**
Referral Doctor	**SELF**	**Sample Reported At**	**2022-09-26 11:38:11**
		Report Status	**Final**

Hepatitis B Profile

Hepatitis B Surface Antibody

SampleType: Serum

INVESTIGATION	RESULT	UNITS	BIOLOGICAL REFERENCE INTERVAL
Hepatitis B Surface Antibody (Anti HBs) Method: CHEMILUMINESCENCE	8.0	mIU/mL	Negative < 10 Positive > 10

Method: CLIA

This assay aids in the diagnosis of Hepatitis B Immune Status

Note: * If the test results are alarming or unexpected, client is advised to contact the laboratory immediately for possible remedial action.

Department of Serology

Name	**MRS B MANJULA**	**Order**	**PTGOC2200091991**
Age / Sex	**35 / F**	**Sample Drawn At**	**2022-09-24 12:21:06**
Collection Centre	**INTGHYD95214**	**Sample Accepted At**	**2022-09-24 17:51:09**
Referral Doctor	**SELF**	**Sample Reported At**	**2022-09-26 11:38:47**
		Report Status	**Final**

Hepatitis B Profile

Hepatitis B Envelope Antigen (ELISA)

SampleType: Serum

INVESTIGATION	RESULT	UNITS	BIOLOGICAL REFERENCE INTERVAL
Hepatitis B Envelope Antigen (HBeAg) Method: ELISA	0.45	Index Value	< 0.9 : Negative 0.9-1.1: Indeterminate > 1.1 : Positive

Note: * If the test results are alarming or unexpected, client is advised to contact the laboratory immediately for possible remedial action.

Department of Serology

Name	**MRS B MANJULA**	**Order**	**PTGOC2200091991**
Age / Sex	**35 / F**	**Sample Drawn At**	**2022-09-24 12:21:06**
Collection Centre	**INTGHYD95214**	**Sample Accepted At**	**2022-09-26 11:31:11**
Referral Doctor	**SELF**	**Sample Reported At**	**2022-09-26 11:40:16**
		Report Status	**Final**

Hepatitis B Profile

Hepatitis B Envelope Antibody (ELISA)

SampleType: Serum

INVESTIGATION	RESULT	UNITS	BIOLOGICAL REFERENCE INTERVAL
Hepatitis B envelope Antibody (AntiHBe) Method: ELISA	1.50	Index Value	< 0.9 : Negative 0.9-1.1: Indeterminate > 1.1 : Positive

Method: ELISA

Note: * If the test results are alarming or unexpected, client is advised to contact the laboratory immediately for possible remedial action.

Department of Serology

Name	**MRS B MANJULA**	**Order**	**PTGOC2200091991**
Age / Sex	**35 / F**	**Sample Drawn At**	**2022-09-24 12:21:06**
Collection Centre	**INTGHYD95214**	**Sample Accepted At**	**2022-09-26 11:35:48**
Referral Doctor	**SELF**	**Sample Reported At**	**2022-09-26 11:41:38**
		Report Status	**Final**

Hepatitis B Profile

Hepatitis B Core Antibody, Total

SampleType: Serum

INVESTIGATION	RESULT	UNITS	BIOLOGICAL REFERENCE INTERVAL
Hepatitis B Core Antibody Total (HBcAb-Total) Method: CHEMILUMINESCENCE	1.45	U/mL	< 0.85 : Non - Reactive 0.85 - 1.15 : Indeterminate > 1.15 : Reactive

Method: CLIA

This assay tests for IgG and IgM antibodies but does not differentiate between them.
Anti-HBc determinations are indicated for the screening of blood and blood products intended for transfusion and to aid in the diagnosis of current or previous hepatitis B viral infection

*** END OF THE REPORT ****

M Nageshwar Rao
Lab Incharge

Dr G Srinivas
Pathologist

Note: * If the test results are alarming or unexpected, client is advised to contact the laboratory immediately for possible remedial action.

Conditions of Reporting

1. Laboratory reports will aid in diagnosis of clinical conditions in conjunction with clinical signs, symptoms and related investigations. They are best interpreted by qualified medical professionals who understand reporting units, reference ranges and limitations of technologies and their correlation with other clinical findings.
2. The interpretations provided by MedPlus are for the guidance of patients and referring doctors. MedPlus nor its affiliates assume any liability or responsibility for any damage of any nature whatsoever that may be incurred in any person as a result of the use of the information provided in the report.
3. It is presumed that the test(s) performed are, on the specimen(s)/sample(s) belonging to the patient named or identified and the verification of the particulars have been carried out by the patient or his/her representative at the point of generation of the side specimen(s) or sample(s).
4. The results of tests may vary from lab to lab and also from time to time for the same parameters for the same patient. Assays are performed with reasonable care and in accordance with standard procedures. The reported results are dependent on individual assay methods, equipment used, method specificity, sensitivity, drug interaction and the quality of the specimen(s)/samples(s) received.
5. Should the results indicate unexpected abnormality, the same should be reconfirmed after appropriate clinical correlation.
6. Histopathology specimen(s)/sample(s) will be preserved for one month from the date of testing and slides/ reports will be preserved for five years. Other clinical specimen(s)/sample(s) will be discarded after seven days from the date of testing, unless otherwise specified by the client. Such preservation shall be subject to sample integrity.
7. Preliminary Report, if any indicates that the results are primary and they are yet to be reported for one or more of the tests, or else, as in case with many microbiology test, a "final" culture, identification or drug susceptibility result might be pending. When all results are available the "Preliminary report" will be replaced by "Final Report". Client Shall rely only on the final report.
8. This report is not valid for Medico-legal purposes.
9. Partial reproduction of this report is not permitted.
10. Tests are performed as per the test schedule in the test listing. in unforeseen circumstances such as non-availability of relevant kits, instrument breakdown, natural calamities etc, tests may not be reported as per schedule.
11. The sex of the foetus will not be revealed as per the prenatal diagnostic techniques (PNDT) Act, 1994.
12. All queries pertaining to this report should be directed to MedPlus Health Services Limited.
13. All investigations are limited by the sensitivity and specificity of the assay and the condition of the specimen received by the laboratory. Assay result should be interpreted only in the context of other clinical findings and the clinical status of the patient.
14. Partial reproduction of this report is not permitted.